Trends in Cardiovascular Medicine
Volume 15, Issue 1 , Pages 41-45 , January 2005

The potential of aptamers as anticoagulants

  • Shahid M. Nimjee

      Affiliations

    • University Program of Genetics, Duke University Medical Center, Durham, North Carolina, USA
    • Department of Surgery, Division of Experimental Surgery, Duke University Medical Center, Durham, North Carolina, USA
    • ,
  • Christopher P. Rusconi

      Affiliations

    • Department of Surgery, Division of Experimental Surgery, Duke University Medical Center, Durham, North Carolina, USA
    • Regado Biosciences Inc., Research Triangle Park, North Carolina, USA
    • ,
  • Robert A. Harrington

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    • ,
  • Bruce A. Sullenger

      Affiliations

    • University Program of Genetics, Duke University Medical Center, Durham, North Carolina, USA
    • Department of Surgery, Division of Experimental Surgery, Duke University Medical Center, Durham, North Carolina, USA
    • Corresponding Author InformationAddress correspondence to: Bruce A. Sullenger, Box 2601 DUMC, Durham, NC 27710, USA. Tel.: (+1) 919-684-6344

References 

  1. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992;355:564–566
  2. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258–264
  3. DeAnda A, Coutre SE, Moon MR, et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thor Surg. 1994;58:344–350
  4. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346:818–822
  5. Eyetech Study Group. Preclinical and Phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143–152
  6. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. [comment] Ophthalmology. 2003;110:979–986
  7. Ginsberg JA, Crowther MA, White RH, Ortel TL. Anticoagulation therapy. Hematology. 2001;1:339–357
  8. Gold L, Polisky B, Uhlenbeck O, Yarus M. Diversity of oligonucleotide functions. Annu Rev Biochem. 1995;64:763–797
  9. Gragoudas ES, Adamis AP, Cunningham J, E.T. , et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  10. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870–878
  11. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LL. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood. 1993;81:3271–3276
  12. Harrington RA. Developing drugs to prevent and treat arterial thrombosis. Cardiol Rounds. 2003;7:7
  13. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl. 3):513S–548S
  14. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018
  15. Jellinek D, Green LS, Bell C, et al. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry. 1995;34:11,363–11,372
  16. Jones HU, Muhlestein JB, Jones KW, et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation. 2002;106(Suppl. 1):I19–I22
  17. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. [see comment] [published erratum appears in JAMA 289:1638 (2003)] JAMA. 2003;289:853–863
  18. Moll S, Roberts HR. Overview of anticoagulant drugs for the future. Semin Hematol. 2002;39:145–157
  19. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl. 3):576S–599S
  20. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. [see comment] JAMA. 2004;292:1555–1562
  21. Ruckman J, Green LS, Beeson J, et al. 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20,556–20,567
  22. Rusconi CP, Yeh A, Lyerly HK, et al. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost. 2000;84:841–848
  23. Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. [see comment] Nature. 2002;419:90–94
  24. Rusconi CP, Roberts JD, Pitoc GA, et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol. 2004;22:1423–1428
  25. Schmidt AE, Bajaj SP. Structure–function relationships in Factor IX and Factor IXa. Trends Cardiovasc Med. 2003;13:39–45
  26. Tucker CE, Chen LS, Judkins MB, et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. Chromatogr B Biomed Sci Appl. 1999;732:203–212
  27. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–510
  28. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl. 3):311S–337S

PII: S1050-1738(05)00003-4

doi: 10.1016/j.tcm.2005.01.002

Trends in Cardiovascular Medicine
Volume 15, Issue 1 , Pages 41-45 , January 2005

Article Tools

* Image Usage & Resolution